Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy

ConclusionOur results indicate that an individualised IVIg treatment protocol is clinically non-inferior and 10 –25% more cost-effective than standard dosing regimens in CIDP.

Source: Journal of Neurology - December 17, 2018 Category: Neurology Source Type: research